Melanoma
Conditions
Brief summary
Patients included will undergo biopsy and the molecular analysis will be discussed at the institutional molecular tumor board. The recommandation of the molecular tumor board will be provided to the physician in charge of the patient for final treatment desicion. The main endpoints are the number of patients with actionable molecular alterations, the number of patients with a treatment recommendation, the number of patients receiving the recommended therapy, overall survival of the patients treated according to recommendations or not. For patients treated according to the recommendations: Response rate and progression free survival at 6 months according to RECIST criteria.
Detailed description
Eligible patients have to have a histologically proven metastatic melanoma failing standard treatments. Other inclusion criteria included age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; life expectancy ≥ 24weeks; adequate renal, liver, and bone marrow functions. Previous therapy with intravenous chemotherapy, immunotherapy or major surgery at least 4 weeks before inclusion was allowed. Patients were excluded if they had a history of cardiac disease or metastatic brain or meningeal tumors. The study is approved by the institutional research ethics board. Molecular analysis is performed at the Max Planck Institute for Molecular Genetics Berlin and a comprehensive report is made available with 4-8 weeks. The molecular tumor board interprets the data and transforms them into treatment recommendations by identifying and prioritizing predictive biomarkers. The recommendations rely on the definition of evidence levels attributed to every single aberration and the interdisciplinary discussion of the aberrations with regard to patient situation, availability of drugs, and clinical trials. The recommendations are transmitted to the physician in charge of the patient for the final decision to treat or not the patient accordingly. The main endpoints are the number of patients with actionable molecular alterations, the number of patients with a treatment recommendation, the number of patients receiving the recommended therapy, overall survival of patients treated according to recommendations or not. For patients treated according to the recommendations: Response rate and progression free survival at 6 months according to RECIST criteria.
Interventions
DRUGMolecular guided therapy
Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
Sponsors
Max-Planck Institut
Alacris
Charite University, Berlin, Germany
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histologically proven metastatic melanoma failing standard treatments * age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 * life expectancy ≥ 24 weeks * adequate renal, liver, and bone marrow functions
Exclusion criteria
\- history of cardiac disease or metastatic brain or meningeal tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility (actionable molecular alterations) | Through study completion over 5 years | number of patients with actionable molecular alterations |
| Feasibility (number of patients with a treatment recommendation) | Through study completion over 5 years | number of patients with a treatment recommendation |
| Feasibility (number of patients receiving the recommended therapy) | Through study completion over 5 years | number of patients receiving the recommended therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5 years | Overall survival |
| Response rate | 1 year | Response rate of the patients treated according to the recommendations |
| Progression free survival at 6 months according to RECIST criteria | up to 6 months | PFS according to RECIST criteria for the patients treated according to the recommendations |
Outcome results
None listed